Menu
Back to Journals » Drug Design, Development and Therapy » Volume 5
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
Published 27 February 2011 Volume 2011:5 Pages 111—116
DOI https://doi.org/10.2147/DDDT.S5392
Review by Single anonymous peer review
Peer reviewer comments 4
Lilliana Oliveira, Russell D Cohen
The Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USA
Abstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the first once daily mesalamine product approved by the Food and Drug Administration for the maintenance of UC remission. This review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in UC maintenance.
Keywords: ulcerative colitis, 5-ASA, mesalamine, adherence, compliance, quality of life, costs
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.